Mirion Technologies, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Mirion supplies radiation detection, measurement, analysis and monitoring products and services through its Medical and Technologies segments. Unless otherwise stated, amounts are in U.S. dollars.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $197.2 million | $175.8 million | $379.3 million | $339.0 million |
| Gross profit | $88.0 million | $79.0 million | $167.1 million | $143.4 million |
| Gross margin | 44.6% | 44.9% | 44.1% | 42.3% |
| Operating loss | $10.6 million | $74.6 million | $24.2 million | $108.2 million |
| Net loss | $28.4 million | $59.3 million | $71.3 million | $78.3 million |
| Adjusted EBITDA (non-GAAP) | $44.3 million | $42.6 million | $80.9 million | $77.5 million |
- Q2 revenue grew 12.2% year over year. Medical revenue was $68.0 million, up from $66.8 million; Technologies revenue was $129.2 million, up from $109.0 million. Technologies generated $12.8 million of segment operating income, while Medical recorded a $3.1 million segment operating loss.
- For the first half, operating cash flow was $4.4 million, down from $28.0 million. Investing cash outflow was $12.9 million; capital purchases were $15.8 million. Financing provided $21.8 million, including equity proceeds, partly offset by debt repayments.
- At June 30, cash and cash equivalents were $87.4 million. Gross third-party borrowings were $697.4 million, including a $694.6 million term loan; reported debt net of financing costs was $683.5 million. The term-loan rate was 7.90%. Revolver availability was approximately $79.2 million, and the company reported compliance with debt covenants.
- Current assets were $503.1 million and current liabilities $224.5 million. Backlog was $742.6 million, compared with $737.4 million at December 31, 2022.
Material changes versus the comparable period
- First-half revenue increased $40.3 million, reflecting price increases and organic growth, the SIS acquisition, and higher Technologies sales. Supply constraints, project timing, foreign exchange and the Rehab disposal partly offset growth.
- First-half operating loss improved by $84.0 million, notably because the prior-year period included a $55.2 million goodwill impairment and higher amortization and corporate costs. In Q2 2023, Mirion recorded a $6.2 million loss on the Rehab disposal.
- First-half net loss narrowed by $7.0 million, but higher interest expense and a $19.1 million non-cash loss on warrant fair-value changes weighed on results. The comparable 2022 period included a $39.5 million warrant fair-value gain.
- In February 2023, a registered equity investment raised $150.0 million gross; approximately $127 million was used to repay debt and related interest. The early repayment triggered a $2.6 million debt-extinguishment charge.
Outlook, risks and unusual items
- Management states that operating cash flow, together with long-term debt arrangements, is expected to provide adequate liquidity for the next 12 months. No specific revenue or earnings guidance is provided in the filing.
- Management cites continuing supply-chain disruption, component delays, material and freight inflation, and project execution delays as risks to revenue timing and margins. Price increases have offset some cost pressures.
- Russia-related sanctions and project uncertainty remain significant. Russian-related backlog was approximately $96.0 million; the company reported $0.7 million of net contract assets and receivables after reserves, alongside $12.0 million of advance-payment guarantees and $14.1 million of performance guarantees. A Russian customer asserted a $19.3 million delay-damages claim and demanded repayment of $10.5 million tied to a cancelled Finland project. Management considers the demands without merit, but outcomes and contract impacts remain uncertain.
- Mirion recorded a $6.2 million loss on the Rehab sale after concluding that collection of $7.0 million of deferred payments from Salona was not probable, following Salona’s disclosure of substantial doubt about its ability to continue as a going concern.
- Disclosure controls and procedures were deemed ineffective at June 30, 2023 due to a previously reported material weakness in IT general controls at the company’s French division, involving program change management and user access. Management reported no resulting financial-statement misstatement and is pursuing remediation.
- Other stated risks include higher interest rates and debt service costs, fixed-price contract cost overruns, foreign-exchange exposure, government budget cycles, and the possibility of further sanctions or project cancellations.
Important facts for investors to verify
- Whether operating cash flow improves and working-capital movements support the company’s liquidity outlook.
- Progress on debt reduction, the impact of floating interest rates, and continued covenant compliance.
- Conversion of the $742.6 million backlog into revenue, particularly Russian-related projects and contracts affected by supply or execution delays.
- Resolution and potential financial exposure from the Russian customer claims and the disputed Finland project payments.
- Whether the deferred Rehab-sale proceeds are recovered and whether the French IT-control material weakness is fully remediated.
- Adjusted EBITDA is a non-GAAP measure; assess it alongside GAAP losses, interest costs, cash flow and its disclosed adjustments.